322 related articles for article (PubMed ID: 22434314)
1. Management of hepatocellular carcinoma: beyond sorafenib.
Chan SL; Mok T; Ma BB
Curr Oncol Rep; 2012 Jun; 14(3):257-66. PubMed ID: 22434314
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib: where do we go from here?
Siegel AB; Olsen SK; Magun A; Brown RS
Hepatology; 2010 Jul; 52(1):360-9. PubMed ID: 20578152
[TBL] [Abstract][Full Text] [Related]
3. Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.
Huynh H; Choo SP; Toh HC; Tai WM; Chung AY; Chow PK; Ong R; Soo KC
Curr Cancer Drug Targets; 2011 Oct; 11(8):944-53. PubMed ID: 21834756
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib for liver cancer: the horizon broadens.
Johnson P; Billingham L
Lancet Oncol; 2009 Jan; 10(1):4-5. PubMed ID: 19111238
[No Abstract] [Full Text] [Related]
5. Evolution of systemic therapy of advanced hepatocellular carcinoma.
Yau T; Chan P; Epstein R; Poon RT
World J Gastroenterol; 2008 Nov; 14(42):6437-41. PubMed ID: 19030192
[TBL] [Abstract][Full Text] [Related]
6. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].
Hoffmann K; Glimm H; Radeleff B; Richter G; Heining C; Schenkel I; Zahlten-Hinguranage A; Schirrmacher P; Schmidt J; Büchler MW; Jaeger D; von Kalle C; Schemmer P
BMC Cancer; 2008 Nov; 8():349. PubMed ID: 19036146
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib in hepatocellular carcinoma.
Josephs DH; Ross PJ
Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
[TBL] [Abstract][Full Text] [Related]
8. [Targeted therapies in hepatocellular carcinoma].
Bouattour M; Marijon H; Dreyer C; Faivre S; Raymond E
Presse Med; 2010; 39(7-8):753-64. PubMed ID: 20378303
[TBL] [Abstract][Full Text] [Related]
9. Targeted agents and systemic therapy in hepatocellular carcinoma.
Ang C; O'Reilly EM; Abou-Alfa GK
Recent Results Cancer Res; 2013; 190():225-46. PubMed ID: 22941024
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development.
Ranieri G; Gadaleta-Caldarola G; Goffredo V; Patruno R; Mangia A; Rizzo A; Sciorsci RL; Gadaleta CD
Curr Med Chem; 2012; 19(7):938-44. PubMed ID: 22214462
[TBL] [Abstract][Full Text] [Related]
11. Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib.
Wich C; Agaimy A; Strobel D; Wissniowski TT; Hartmann A; Ocker M
World J Gastroenterol; 2010 Jul; 16(28):3592-6. PubMed ID: 20653070
[TBL] [Abstract][Full Text] [Related]
12. [Hepatocellular carcinoma].
Yamashita T; Arai K; Kaneko S
Nihon Rinsho; 2010 Oct; 68(10):1861-5. PubMed ID: 20954330
[TBL] [Abstract][Full Text] [Related]
13. Targeting receptor tyrosine kinase pathways in hepatocellular carcinoma.
Huynh H; Ong RW; Li PY; Lee SS; Yang S; Chong LW; Luu DA; Jong CT; Lam IW
Anticancer Agents Med Chem; 2011 Jul; 11(6):560-75. PubMed ID: 21554207
[TBL] [Abstract][Full Text] [Related]
14. [Hepatocellular carcinoma - long-term treatable disease].
Fínek J
Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
[TBL] [Abstract][Full Text] [Related]
15. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
Daniele B; Di Maio M
J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
[No Abstract] [Full Text] [Related]
16. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
Yau T; Pang R; Chan P; Poon RT
Expert Opin Pharmacother; 2010 Sep; 11(13):2187-98. PubMed ID: 20707757
[TBL] [Abstract][Full Text] [Related]
17. Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study.
Zhao JD; Liu J; Ren ZG; Gu K; Zhou ZH; Li WT; Chen Z; Xu ZY; Liu LM; Jiang GL
Radiat Oncol; 2010 Feb; 5():12. PubMed ID: 20149262
[TBL] [Abstract][Full Text] [Related]
18. Candidacy for sorafenib in HCC patients: is there a slippery slope beyond a SHARP edge?
Burak KW
Oncology (Williston Park); 2011 Mar; 25(3):296, 298, 300. PubMed ID: 21548474
[No Abstract] [Full Text] [Related]
19. Current status of hepatocellular carcinoma treatment in Japan: case study and discussion-voting system.
Kudo M; Tateishi R; Yamashita T; Ikeda M; Furuse J; Ikeda K; Kokudo N; Izumi N; Matsui O
Clin Drug Investig; 2012 Aug; 32 Suppl 2():37-51. PubMed ID: 22873626
[TBL] [Abstract][Full Text] [Related]
20. Molecular targeted therapies in hepatocellular carcinoma.
Llovet JM; Bruix J
Hepatology; 2008 Oct; 48(4):1312-27. PubMed ID: 18821591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]